首页 > 最新文献

Actas dermo-sifiliograficas最新文献

英文 中文
Linezolid, an Alternative to Ertapenem in Recalcitrant Hidradenitis Suppurativa: A Series of 6 Cases 利奈唑胺替代厄他培南治疗顽固性化脓性汗腺炎6例临床观察。
IF 2.8 Q1 DERMATOLOGY
Actas dermo-sifiliograficas
Pub Date : 2026-05-01 Epub Date: 2025-12-18 DOI: 10.1016/j.ad.2025.104575
T.L. Vega López , L. Aguilar González , R.P. Román Cheuque , D. Jiménez Gallo
{"title":"Linezolid, an Alternative to Ertapenem in Recalcitrant Hidradenitis Suppurativa: A Series of 6 Cases","authors":"T.L. Vega López , L. Aguilar González , R.P. Román Cheuque , D. Jiménez Gallo","doi":"10.1016/j.ad.2025.104575","DOIUrl":"10.1016/j.ad.2025.104575","url":null,"abstract":"","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 5","pages":"Article 104575"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145800360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adnexal Tumours: The Unconditional Help of Dermoscopy 附件肿瘤：皮肤镜的无条件帮助。
IF 2.8 Q1 DERMATOLOGY
Actas dermo-sifiliograficas
Pub Date : 2026-05-01 Epub Date: 2025-12-18 DOI: 10.1016/j.ad.2025.104576
L.M. Nieto-Benito , M. Garrido-Ruiz , M. Huerta-Brogeras , A. Tomás-Velázquez , P. Redondo-Bellón
{"title":"Adnexal Tumours: The Unconditional Help of Dermoscopy","authors":"L.M. Nieto-Benito , M. Garrido-Ruiz , M. Huerta-Brogeras , A. Tomás-Velázquez , P. Redondo-Bellón","doi":"10.1016/j.ad.2025.104576","DOIUrl":"10.1016/j.ad.2025.104576","url":null,"abstract":"","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 5","pages":"Article 104576"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145800392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Deep Morphea Induced by Simvastatin 辛伐他汀引起的深度睡眠。
IF 2.8 Q1 DERMATOLOGY
Actas dermo-sifiliograficas
Pub Date : 2026-05-01 Epub Date: 2025-12-17 DOI: 10.1016/j.ad.2025.104571
M. Álvarez-Salafranca , A. Lapeña-Casado , M. García-García , A. Montes-Torres
{"title":"Deep Morphea Induced by Simvastatin","authors":"M. Álvarez-Salafranca , A. Lapeña-Casado , M. García-García , A. Montes-Torres","doi":"10.1016/j.ad.2025.104571","DOIUrl":"10.1016/j.ad.2025.104571","url":null,"abstract":"","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 5","pages":"Article 104571"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145792627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bilateral Hand Swelling as a Sign of Systemic Amyloidosis 双侧手肿胀是系统性淀粉样变的征象。
IF 2.8 Q1 DERMATOLOGY
Actas dermo-sifiliograficas
Pub Date : 2026-05-01 Epub Date: 2025-12-18 DOI: 10.1016/j.ad.2025.104577
M.A. Sirvent-Sáez, A.I. Sánchez-Del-Campo, D. Moreno-Ramírez
{"title":"Bilateral Hand Swelling as a Sign of Systemic Amyloidosis","authors":"M.A. Sirvent-Sáez, A.I. Sánchez-Del-Campo, D. Moreno-Ramírez","doi":"10.1016/j.ad.2025.104577","DOIUrl":"10.1016/j.ad.2025.104577","url":null,"abstract":"","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 5","pages":"Article 104577"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145800407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Paramedian Forehead Flap With Intraoperative Frontal Expansion 术中额部扩张的旁位前额皮瓣。
IF 2.8 Q1 DERMATOLOGY
Actas dermo-sifiliograficas
Pub Date : 2026-05-01 Epub Date: 2025-12-18 DOI: 10.1016/j.ad.2025.104578
D. Moreno-Ramírez , A. Fernández-Orland , F. Vizcaíno , L. Ferrándiz
{"title":"Paramedian Forehead Flap With Intraoperative Frontal Expansion","authors":"D. Moreno-Ramírez , A. Fernández-Orland , F. Vizcaíno , L. Ferrándiz","doi":"10.1016/j.ad.2025.104578","DOIUrl":"10.1016/j.ad.2025.104578","url":null,"abstract":"","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 5","pages":"Article 104578"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145800377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Traditional Practices in Dermatology and Wound Care: Are They Evidence-Based? 皮肤病学和伤口护理的传统做法：它们是基于证据的吗？
IF 2.8 Q1 DERMATOLOGY
Actas dermo-sifiliograficas
Pub Date : 2026-05-01 Epub Date: 2025-12-18 DOI: 10.1016/j.ad.2025.104573
A. García-Mares , E. Conde Montero
{"title":"Traditional Practices in Dermatology and Wound Care: Are They Evidence-Based?","authors":"A. García-Mares , E. Conde Montero","doi":"10.1016/j.ad.2025.104573","DOIUrl":"10.1016/j.ad.2025.104573","url":null,"abstract":"","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 5","pages":"Article 104573"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145800390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phenotypes in Symptomatic Dermographism 症状性皮肤特征的表型。
IF 2.8 Q1 DERMATOLOGY
Actas dermo-sifiliograficas
Pub Date : 2026-05-01 Epub Date: 2025-12-17 DOI: 10.1016/j.ad.2025.104566
M. Prados-Castaño, M. Reguero Capilla, E. Menéndez-Rivero, L. Ruiz Del Barrio
{"title":"Phenotypes in Symptomatic Dermographism","authors":"M. Prados-Castaño, M. Reguero Capilla, E. Menéndez-Rivero, L. Ruiz Del Barrio","doi":"10.1016/j.ad.2025.104566","DOIUrl":"10.1016/j.ad.2025.104566","url":null,"abstract":"","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 5","pages":"Article 104566"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145792786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost-consequence Analysis of Secukinumab vs Adalimumab in Moderate-to-severe Hidradenitis Suppurativa secukinumab与阿达木单抗治疗中重度化脓性汗腺炎的成本-后果分析
IF 2.8 Q1 DERMATOLOGY
Actas dermo-sifiliograficas
Pub Date : 2026-05-01 Epub Date: 2025-12-20 DOI: 10.1016/j.ad.2025.104582
A. Martorell , A. Molina-Leyva , A. Jiménez Morales , C. Blanch

Background and objective

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease. Treatment for moderate-to-severe HS includes biologic therapies (adalimumab and secukinumab), resulting in increased disease management costs. Our aim was to estimate the difference between secukinumab and adalimumab in terms of pharmacological costs and costs per responding patient 1 year into therapy from the Spanish National Health System (NHS) perspective.

Material and methods

We designed a decision tree comparing different treatment sequences, starting with a different first-line therapy. Patients switched arms based on achieving HS clinical response ≥50% (based on the SUNSHINE, SUNRISE, and PIONEER clinical trials results). A cohort of 100 patients was considered. Only treatment costs in € (2023 base year) were considered for the analysis. A panel of experts validated the model structure and parameters.

Results

After 52-weeks into therapy, treatment sequences in the secukinumab group resulted in a total cost of €1,198,912, corresponding to €16,858 per responder. Total costs in the adalimumab treatment group were 2.5% higher, corresponding to €19,701 per responder. A total of 80% of responders who start treatment with secukinumab do not change treatment, while only 31% of responders who start treatment with adalimumab stay on the same treatment.

Conclusions

The results of our financial assessment can help decision makers in selecting the most efficient therapeutic approach for treating patients with moderate-to-severe HS and poses secukinumab as a suitable therapeutic option for the Spanish NHS.
背景与目的：化脓性汗腺炎（HS）是一种慢性炎症性皮肤病。中重度HS的治疗包括生物疗法（阿达木单抗和secukinumab），导致疾病管理成本增加。我们的目的是从西班牙国家卫生系统（NHS）的角度估计secukinumab和adalimumab在药理学成本和治疗1年后每位应答患者的成本方面的差异。材料和方法：我们设计了一个决策树，比较不同的治疗序列，从不同的一线治疗开始。患者在达到HS临床反应≥50%（基于SUNSHINE、SUNRISE和PIONEER临床试验结果）的基础上切换治疗组。考虑了100例患者的队列。分析中只考虑了欧元（2023基准年）的治疗费用。专家小组对模型结构和参数进行了验证。结果：在治疗52周后，secukinumab组的治疗序列导致总成本为1,198,912欧元，对应于每位应答者16,858欧元。阿达木单抗治疗组的总成本高出2.5%，相当于每位应答者19,701欧元。总共80%开始使用secukinumab治疗的应答者不改变治疗，而开始使用阿达木单抗治疗的应答者中只有31%继续使用相同的治疗。结论：我们的财务评估结果可以帮助决策者选择最有效的治疗方法来治疗中重度HS患者，并使secukinumab成为西班牙NHS的合适治疗选择。
{"title":"Cost-consequence Analysis of Secukinumab vs Adalimumab in Moderate-to-severe Hidradenitis Suppurativa","authors":"A. Martorell ,&nbsp;A. Molina-Leyva ,&nbsp;A. Jiménez Morales ,&nbsp;C. Blanch","doi":"10.1016/j.ad.2025.104582","DOIUrl":"10.1016/j.ad.2025.104582","url":null,"abstract":"<div><h3>Background and objective</h3><div>Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease. Treatment for moderate-to-severe HS includes biologic therapies (adalimumab and secukinumab), resulting in increased disease management costs. Our aim was to estimate the difference between secukinumab and adalimumab in terms of pharmacological costs and costs per responding patient 1 year into therapy from the Spanish National Health System (NHS) perspective.</div></div><div><h3>Material and methods</h3><div>We designed a decision tree comparing different treatment sequences, starting with a different first-line therapy. Patients switched arms based on achieving HS clinical response ≥50% (based on the SUNSHINE, SUNRISE, and PIONEER clinical trials results). A cohort of 100 patients was considered. Only treatment costs in € (2023 base year) were considered for the analysis. A panel of experts validated the model structure and parameters.</div></div><div><h3>Results</h3><div>After 52-weeks into therapy, treatment sequences in the secukinumab group resulted in a total cost of €1,198,912, corresponding to €16,858 per responder. Total costs in the adalimumab treatment group were 2.5% higher, corresponding to €19,701 per responder. A total of 80% of responders who start treatment with secukinumab do not change treatment, while only 31% of responders who start treatment with adalimumab stay on the same treatment.</div></div><div><h3>Conclusions</h3><div>The results of our financial assessment can help decision makers in selecting the most efficient therapeutic approach for treating patients with moderate-to-severe HS and poses secukinumab as a suitable therapeutic option for the Spanish NHS.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 5","pages":"Article 104582"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145809161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Translation, Cross-cultural Adaptation, Correlation With Other PROMs and Validation of the MF/SS-CTCL-QoL Questionnaire on Quality of Life in Mycosis Fungoides (MF) and Sézary Syndrome (SS) MF/SS- ctcl - qol真菌病（MF）和ssamzary综合征（SS）生活质量问卷的翻译、跨文化适应、与其他PROMs的相关性和验证。
IF 2.8 Q1 DERMATOLOGY
Actas dermo-sifiliograficas
Pub Date : 2026-05-01 Epub Date: 2025-12-23 DOI: 10.1016/j.ad.2025.104584
M.M. Onteniente-Gomis , S.I. Palencia Perez , F.J. Ortiz de Frutos , C.M. García Álvarez , C. Martin Arriscado Arroba , C. Varela Rodriguez , P.L. Ortiz-Romero

Background

MF/SS-CTCL-QoL is the first specific questionnaire to measure the quality of life (QoL) of patients with mycosis fungoides (MF) and Sézary syndrome (SS). It was developed by the Cutaneous Lymphoma Foundation.

Objectives

(1) Translate and cross-culturally adapt the MF/SS-CTCL-QoL to Spanish (Spain). (2) To study correlation and concordance of the MF/SS-CTCL-QoL with PROM (Patient Reported Outcome Measurements): EORTC QLQ-C30, Dermatology Life Quality Index (DLQI) and Skindex-29.

Material and methods

Using a 10-step procedure, including expert meetings and surveys of adult patients with MF or SS, a Spanish version of the MF/SS-CTCL-QoL was developed. Subsequently, its comprehensibility, completeness and relevance were evaluated. A correlation study was performed using Spearman's rho coefficient and concordance using the intraclass correlation coefficient (ICC), between MF/SS-CTCL-QoL and the EORTC QLQ-C30, DLQI and Skindex-29 questionnaires.

Results

Translation was satisfactory for professionals and patients, with minimal adaptations required. Excellent correlation (0.8499) was observed between MF/SS-CTCL-QoL and Skindex-29, good (0.7394) with DLQI and poor (0.5602) with EORTC QLQ-C30. Agreement was moderate (0.699) with DLQI, significant (0.865) with Skindex-29 and low (0.568) with EORTC QLQ-C30.

Conclusions

The Spanish version of MF/SS-CTCL-QoL represents a useful tool for the clinical management of patients with MF and SS. It is linguistically equivalent to the original, assesses the same dimensions with an adequate level of comprehensibility. There is an excellent correlation with Skindex-29, good with DLQI and poor with EORTC QLQ-C30.
背景：MF/SS- ctcl -QoL是第一个测量蕈样真菌病（MF）和ssamzary综合征（SS）患者生活质量（QoL）的特异性问卷。它是由皮肤淋巴瘤基金会开发的。目标：1)翻译和跨文化适应MF/SS-CTCL-QoL到西班牙语（西班牙）。2)研究MF/SS-CTCL-QoL与PROM（患者报告结果测量）：EORTC QLQ-C30、Dermatology Life Quality Index （DLQI）和skin Index -29的相关性和一致性。材料和方法：采用10步程序，包括专家会议和对成年MF或SS患者的调查，制定了西班牙语版MF/SS- ctcl - qol。随后，对其可理解性、完整性和相关性进行了评价。采用Spearman’s rho系数对MF/SS-CTCL-QoL与EORTC QLQ-C30、DLQI和skinindex -29问卷进行相关性研究，采用类内相关系数（ICC）进行一致性研究。结果：翻译对专业人员和患者都是满意的，只需要很少的调整。MF/SS-CTCL-QoL与skinindex -29相关性极好（0.8499），与DLQI相关性良好（0.7394），与EORTC QLQ-C30相关性较差（0.5602）。与DLQI的一致性为中等（0.699），与Skindex-29的一致性为显著（0.865），与EORTC QLQ-C30的一致性为低（0.568）。结论：西班牙语版MF/SS- ctcl - qol是MF和SS患者临床管理的有用工具。它在语言上与原始版本相当，评估相同的维度，具有足够的可理解性。与skinindex -29相关性极好，与DLQI相关性良好，与EORTC qq - c30相关性较差。
{"title":"Translation, Cross-cultural Adaptation, Correlation With Other PROMs and Validation of the MF/SS-CTCL-QoL Questionnaire on Quality of Life in Mycosis Fungoides (MF) and Sézary Syndrome (SS)","authors":"M.M. Onteniente-Gomis ,&nbsp;S.I. Palencia Perez ,&nbsp;F.J. Ortiz de Frutos ,&nbsp;C.M. García Álvarez ,&nbsp;C. Martin Arriscado Arroba ,&nbsp;C. Varela Rodriguez ,&nbsp;P.L. Ortiz-Romero","doi":"10.1016/j.ad.2025.104584","DOIUrl":"10.1016/j.ad.2025.104584","url":null,"abstract":"<div><h3>Background</h3><div>MF/SS-CTCL-QoL is the first specific questionnaire to measure the quality of life (QoL) of patients with mycosis fungoides (MF) and Sézary syndrome (SS). It was developed by the Cutaneous Lymphoma Foundation.</div></div><div><h3>Objectives</h3><div>(1) Translate and cross-culturally adapt the MF/SS-CTCL-QoL to Spanish (Spain). (2) To study correlation and concordance of the MF/SS-CTCL-QoL with PROM (Patient Reported Outcome Measurements): EORTC QLQ-C30, Dermatology Life Quality Index (DLQI) and Skindex-29.</div></div><div><h3>Material and methods</h3><div>Using a 10-step procedure, including expert meetings and surveys of adult patients with MF or SS, a Spanish version of the MF/SS-CTCL-QoL was developed. Subsequently, its comprehensibility, completeness and relevance were evaluated. A correlation study was performed using Spearman's rho coefficient and concordance using the intraclass correlation coefficient (ICC), between MF/SS-CTCL-QoL and the EORTC QLQ-C30, DLQI and Skindex-29 questionnaires.</div></div><div><h3>Results</h3><div>Translation was satisfactory for professionals and patients, with minimal adaptations required. Excellent correlation (0.8499) was observed between MF/SS-CTCL-QoL and Skindex-29, good (0.7394) with DLQI and poor (0.5602) with EORTC QLQ-C30. Agreement was moderate (0.699) with DLQI, significant (0.865) with Skindex-29 and low (0.568) with EORTC QLQ-C30.</div></div><div><h3>Conclusions</h3><div>The Spanish version of MF/SS-CTCL-QoL represents a useful tool for the clinical management of patients with MF and SS. It is linguistically equivalent to the original, assesses the same dimensions with an adequate level of comprehensibility. There is an excellent correlation with Skindex-29, good with DLQI and poor with EORTC QLQ-C30.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 5","pages":"Article 104584"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145832070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Toxic Epidermal Necrolysis Due to Pembrolizumab-Associated Chemotherapy 派姆单抗相关化疗引起的中毒性表皮坏死松解。
IF 2.8 Q1 DERMATOLOGY
Actas dermo-sifiliograficas
Pub Date : 2026-05-01 Epub Date: 2025-12-17 DOI: 10.1016/j.ad.2025.104570
L. Bernal Masferrer, B. Aldea Manrique, M. Claudia Matei, T. Gracia Cazaña
{"title":"Toxic Epidermal Necrolysis Due to Pembrolizumab-Associated Chemotherapy","authors":"L. Bernal Masferrer,&nbsp;B. Aldea Manrique,&nbsp;M. Claudia Matei,&nbsp;T. Gracia Cazaña","doi":"10.1016/j.ad.2025.104570","DOIUrl":"10.1016/j.ad.2025.104570","url":null,"abstract":"","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 5","pages":"Article 104570"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145792779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
类型
全部 化学•材料 生命科学 医学 物理 工程技术 环境•农林 材料科学 地球科学 法学 管理学 化学 环境科学与生态学 计算机科学 教育学 经济学 农林科学 人文科学 生物学 数学 物理与天体物理 心理学 综合性期刊 其他 工业工程 理学 历史学 农学 文学 信息工程
数据库
全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley
期刊
Actas dermo-sifiliograficas
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们：info@booksci.cn
Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1